Literature DB >> 15294960

Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.

Yu-Pei Liao1, Chun-Chieh Wang, Lisa H Butterfield, James S Economou, Antoni Ribas, Wilson S Meng, Keisuke S Iwamoto, William H McBride.   

Abstract

Radiation is generally considered to be an immunosuppressive agent that acts by killing radiosensitive lymphocytes. In this study, we demonstrate the noncytotoxic effects of ionizing radiation on MHC class I Ag presentation by bone marrow-derived dendritic cells (DCs) that have divergent consequences depending upon whether peptides are endogenously processed and loaded onto MHC class I molecules or are added exogenously. The endogenous pathway was examined using C57BL/6 murine DCs transduced with adenovirus to express the human melanoma/melanocyte Ag recognized by T cells (AdVMART1). Prior irradiation abrogated the ability of AdVMART1-transduced DCs to induce MART-1-specific T cell responses following their injection into mice. The ability of these same DCs to generate protective immunity against B16 melanoma, which expresses murine MART-1, was also abrogated by radiation. Failure of AdVMART1-transduced DCs to generate antitumor immunity following irradiation was not due to cytotoxicity or to radiation-induced block in DC maturation or loss in expression of MHC class I or costimulatory molecules. Expression of some of these molecules was affected, but because irradiation actually enhanced the ability of DCs to generate lymphocyte responses to the peptide MART-1(27-35) that is immunodominant in the context of HLA-A2.1, they were unlikely to be critical. The increase in lymphocyte reactivity generated by irradiated DCs pulsed with MART-1(27-35) also protected mice against growth of B16-A2/K(b) tumors in HLA-A2.1/K(b) transgenic mice. Taken together, these results suggest that radiation modulates MHC class I-mediated antitumor immunity by functionally affecting DC Ag presentation pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294960     DOI: 10.4049/jimmunol.173.4.2462

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Animal models for medical countermeasures to radiation exposure.

Authors:  Jacqueline P Williams; Stephen L Brown; George E Georges; Martin Hauer-Jensen; Richard P Hill; Amy K Huser; David G Kirsch; Thomas J Macvittie; Kathy A Mason; Meetha M Medhora; John E Moulder; Paul Okunieff; Mary F Otterson; Michael E Robbins; James B Smathers; William H McBride
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

2.  Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro.

Authors:  Jianping Huang; Qiong J Wang; Shicheng Yang; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2011-05       Impact factor: 4.456

3.  Radiation enhances regulatory T cell representation.

Authors:  Evelyn L Kachikwu; Keisuke S Iwamoto; Yu-Pei Liao; John J DeMarco; Nzhde Agazaryan; James S Economou; William H McBride; Dörthe Schaue
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-17       Impact factor: 7.038

4.  T-cell responses to survivin in cancer patients undergoing radiation therapy.

Authors:  Dörthe Schaue; Begonya Comin-Anduix; Antoni Ribas; Li Zhang; Lee Goodglick; James W Sayre; Annelies Debucquoy; Karin Haustermans; William H McBride
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 5.  Adapting conventional cancer treatment for immunotherapy.

Authors:  Jian Qiao; Zhida Liu; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2016-02-24       Impact factor: 4.599

6.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

Review 7.  Radiation and inflammation.

Authors:  Dörthe Schaue; Ewa D Micewicz; Josephine A Ratikan; Michael W Xie; Genhong Cheng; William H McBride
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

Review 8.  Adequate antigen availability: a key issue for novel approaches to tumor vaccination and tumor immunotherapy.

Authors:  Roberto S Accolla; Giovanna Tosi
Journal:  J Neuroimmune Pharmacol       Date:  2012-12-07       Impact factor: 4.147

9.  Treatment of 4T1 metastatic breast cancer with combined hypofractionated irradiation and autologous T-cell infusion.

Authors:  Alexander Filatenkov; Jeanette Baker; Antonia M Müller; G-One Ahn; Holbrook Kohrt; Suparna Dutt; Kent Jensen; Sussan Dejbakhsh-Jones; Robert S Negrin; Judith A Shizuru; Edgar G Engleman; Samuel Strober
Journal:  Radiat Res       Date:  2014-07-03       Impact factor: 2.841

Review 10.  Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Authors:  Robert E Roses; Jashodeep Datta; Brian J Czerniecki
Journal:  Radiat Res       Date:  2014-07-03       Impact factor: 2.841

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.